Yahoo
ASX - Delayed Quote AUD

Neuren Pharmaceuticals Limited (NEU.AX)

20.36 +0.22 (+1.09%)
At close: October 30 at 4:10:11 PM GMT+11
View in AlphaSpace Currency in AUD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
69,512
64,634
213,243
231,925
14,553
Gross Profit
69,512
64,634
213,243
231,925
14,553
Operating Expense
55,691
42,633
37,693
32,714
16,159
Operating Income
13,821
22,001
175,550
199,211
-1,606
Net Non Operating Interest Income Expense
11,427
12,159
11,014
5,687
391
Other Income Expense
1,540
4,746
-3,646
225
1,389
Pretax Income
26,814
38,929
182,940
205,140
184
Tax Provision
6,557
8,493
40,897
48,059
0
Net Income Common Stockholders
20,257
30,436
142,043
157,081
184
Basic EPS
0.16
0.24
--
1.24
0.00
Diluted EPS
0.15
0.23
1.09
1.20
0.00
Basic Average Shares
128,340.16
128,241.47
127,769.43
127,069.51
125,965.68
Diluted Average Shares
129,958.83
130,795.02
--
130,791.84
125,965.68
Net Income from Continuing & Discontinued Operation
20,257
30,436
142,043
157,081
184
Normalized Income
20,257
30,436
142,043
157,081
184
Interest Income
11,427
12,159
11,014
5,687
391
Net Interest Income
11,427
12,159
11,014
5,687
391
EBIT
13,821
22,001
175,550
199,211
-1,606
EBITDA
13,847
22,024
175,572
199,228
-1,596
Reconciled Depreciation
26
23
22
17
10
Net Income from Continuing Operation Net Minority Interest
20,257
30,436
142,043
157,081
184
Normalized EBITDA
13,847
22,024
175,572
199,228
-1,596
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2022 - 2/1/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: